WideCells Group


Leadership

Our business wouldn't be where it is today if it wasn't for the hard work and sheer determination of our dedicated people. Our leadership team are experts in their field, making things happen and keeping our stakeholders happy.

WideCells Group's PLC executive team

WideCells Group's PLC executive team boasts experts from many facets of the healthcare, medical, science and technology industries, all of whom have a proven track record in healthcare product development.

As seasoned business people, entrepreneurs, innovators and scientists,
they guide WideCells Group in the development of our products and services,
bringing them from the research and development stage to the real world of
healthcare quickly, efficiently and with enhanced value.

Peter Presland

Peter Presland

Non-Executive Chairman

Peter has a track record of building both large and small companies through the development of corporate strategies to create shareholder value. Over his 45-year career he has held numerous chairmanships and directorships spanning a range of sectors including pharmaceutical, healthcare and insurance. He was CFO then CEO for 17 years at C E Heath PLC, a London Stock Exchange listed major international insurance group, and has held previous non-executive positions at East Kent Hospitals University Foundation NHS Trust, one of the largest Foundation Trusts in the UK, John Holman & Sons Limited, the (then) oldest independent Lloyd’s insurance broker, and Chairman at Link, the UK ATM network.


Read more
João Andrade

João Andrade

Chief Executive Officer

João, one of the co-founders of the WideCells business, has a strong background in marketing and international business development, and brings his considerable business experience, strategic thinking and industry specific knowledge. João has over eight years senior experience in the stem cell market, and, prior to founding WideCells, served in key roles at two European cord blood banks and service providers, with operations in several countries. With an extensive contact network and unrivalled knowledge of the stem cell industry, João is committed to creating the world’s first end-to-end stem cell service soluction, which drives change and development within this growing industry.


Read more
Jeremy Lea

Jeremy Lea

Chief Operating Officer

Dr. Lea has extensive sales and management experience and success in delivering tangible financial, operational and efficiency-driven improvements within the healthcare sector. He already has an in-depth understanding of the Group having led WideCells Limited, the Group’s stem cell storage and research division, and has also helped in a number of senior management positions. Prior to joining the Group, he was the Commercial Leader for Cole-Parmer Ltd, a global manufacturer of laboratory products, tasked with driving all commercial activities for sales and marketing within the EMEA region. Other roles held include Sales and Marketing Manager of Nu Instruments Ltd, a market leading designer and manufacturer of high-performance mass spectrometers and accessories, and Global Head of Sales of the AIC division of Bruker Biospin, Karlsruhe/Billerica, part of the Bruker Corporation.


Read more
Alan Greenberg

Alan Greenberg

Group Chief Business Development Officer and VP Wideacademy

Alan has a wealth of experience nurturing start-up companies predominantly in Education Technologies and Healthcare sectors globally. Alan was previously Head of Higher Education at Apple EMEA, then Apple Education Director, China. His team were responsible for building the technologies behind Podcasting and iTunes U. Though predominantly continuing the growth of Wideacademy, Alan’s responsibilities include business development strategies for the Group, designing and implementing processes to support growth.


Read more
David Bridgland

David Bridgland

Chief Financial Officer
 

David studied engineering at Cambridge University and is a Chartered Accountant. He has over 20 years of business experience in a range of companies, from privately owned and venture capital backed companies to major listed companies, including Smiths Group, Autoliv and Honeywell. David's key focus is early stage businesses with innovative technologies, and he has experience in raising funding, organic business growth, acquisitions and has achieved successful trade sale exists for investors.


Read more
Dr Peter Hollands

Prof. Peter Hollands

Chief Scientific Officer
 

Peter trained at Cambridge University under the supervision of Professor Sir Robert Edwards FRS, the inventor of IVF and Nobel Laureate, gaining a PhD from Cambridge University in stem cell technology. Peter held a post-doctorate position as a Senior Embryologist at the first IVF clinic in the world, Bourn Hall Clinic, and has carried out research in stem cell technology, has written numerous papers and book chapters on stem cell technology, and has been invited to lecture on stem cell technology in the Vatican, House of Lords and the Canadian Parliament. He has also been involved in clinical transplantation as Quality Manager in the Bone Marrow Transplantation Unit at Great Ormond Street Hospital for Children. Most recently, Peter was Chief Scientific Officer of Smart Cells Information Ltd., a UK cord blood bank, and Cells for Life Ltd. in Canada.


Read more
Malcolm Glaister

Malcolm Glaister

Non-Executive Director
 

Malcolm has extensive capital markets experience having held a number of management roles across a broad spectrum of leading investment and trading business. In 2012, he founded Farm Street LLP of which he is currently CEO, delivering financial advice to UK entrepreneurs and businesses, covering corporate finance, treasury debt, and asset management. Malcolm is also Founding Partner of the Eight Great Technologies Investment Fund LP, a venture capital fund focusing on investing in emerging UK tech companies. Prior to this, Malcolm was Head of Private Banking for Lloyds Bank PLC, and Head of Family Offices and a senior private banker at JP Morgan.


Read more
David Henriques

David Henriques

Non-Executive Director and Chairman of the Group’s Audit/Risk Committee

As an experienced corporate financier who is involved with the digitalisation of insurance products, Mr. Henriques brings a unique skill set to support the continued growth of WideCells Group. He is a co-Founder and Director of Cairn Capital Ltd (‘Cairn’), a full-service credit asset management firm, and was formerly co-Global Head of Structured Credit Products with the Royal Bank of Scotland. Prior to this, he held various senior positions in corporate finance and insurance companies. He is currently a Non-Executive Director of Azur Group Holdings Limited, an Insurance Managing Digital Agency, which partners with carriers and brokers to build, underwrite and distribute digital insurance products.


Read more
Dr Marilyn Orcharton

Dr Marilyn Orcharton

Non-Executive Director
 

A serial entrepreneur, Marilyn is a qualified dentist with a medal of Honour from the British Dental Association, and her first business was a dental practice. She co-founded Denplan Limited in 1986, which is still the UK's market leader in dental insurance, with a multi-million pound annual turnover. Marilyn sold her stake in Denplan in 1992 and founded Kite Consultants Ltd, which has researched and developed ISOPLAN, a unique business management software package for professional outlets: dentists, doctors, nursing homes and lawyers. She is a founder member of the Entrepreneurial Exchange and has been an honouree of the Leading Women Entrepreneurs. Marilyn was also a visiting surgeon at the University of Glasgow and the first woman to be a dental advisor to the Medical Defence Union and president of the Glasgow Chamber of Commerce. She also has a diploma in marketing and is a member of the Chartered Institute of Marketing.


Read more

Scientific Advisory Committee



The Scientific Advisory Committee is responsible for identifying and advising the Board
on new developments within the stem cell sector to ensure that the
Group continues to address market demand and offer the most competitive and innovative
portfolio of services whilst maintaining a consistent level of operational excellence.

Tristan Mckay

Tristan Mckay

Tristan is Professor of Stem Cell Biology and Head of Genes, Cell & Molecular Biology Group at the Biomedical Research Centre, School of Healthcare Science, Manchester Metropolitan University. Tristan leads a group of researchers investigating the signalling pathways underlying cellular reprogramming during differentiation and de-differentiation in development and disease. Previously, he was Reader in Molecular and Cell Services at St. George’s University of London and Senior Lecturer at the Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London. Tristan is a member of numerous international organisations focused on stem cell research and gene therapy and has published original research in leading publications such as Stem Cell Research. Tristan is chair of the Scientific Advisory Committee.


Read more
Dr. Ahmed Al-Alawi

Dr. Ahmed Al-Alawi

Ahmed has significant biotechnical and management experience having previously led a team for the development of a manufacturing process for a major product at Genzyme. He consults and advises on strategic investments, management, manufacturing and innovation, and works closely with leading universities, organisations and businesses on shaping the future of healthcare and innovation globally. Ahmed founded the Middle East Thrombosis Research Institution in the UAE, which boasts 18 research centres. During 2011 to 2013 he was a Programme Director of the HealthCare Programme at the Gulf Research Centre in Cambridge. Ahmed has cross functional experience in international Fortune 500 & FTSE companies having previously held roles at Philips Electronics and being a recipient of a scholarship from Shell International. He also has notable connections in the Middle East having worked within the Omani Government and co-founded RAY International LLC. He is deputy chair of the Scientific Advisory Committee and also Group Managing Director of WideCells Group MENA & Asia-Pacific.


Read more
Dr. Niranjan Bhattacharya

Dr. Niranjan Bhattacharya

Niranjan is a leading Obstetrician and Gynaecologist in Kolkata, India who with over 30 years experience has won several industry awards and was named one of the top five cord blood industry influencers by market researcher, BioInformant. He founded the Department of Regenerative Medicine and Translational Science at the Kolkata school of Tropical Medicine, India (www.stmkolkata.org) in April 2012 and has written extensively on the topic of cord blood and presented at leading institutions worldwide, including Harvard, University of London, University of Glasgow, and Chinese University of Hong Kong. He is currently pioneering highly innovative research projects, such as the use of foetal cell and tissue therapy in degenerative disease; placental umbilical cord blood as an emergency substitute of adult whole blood and; the role of amniotic fluid as a burn dressing.


Read more
Dr. Richard Shaffer

Dr. Richard Shaffer

Richard is a consultant in Clinical Oncology at St Luke’s Cancer Centre, and Clinical Lead for Radiotherapy Innovation at GenesisCare UK. Prior to this he was Specialist Registrar in Clinical Oncology at Charing Cross Hospital, University College London Hospital, and Royal Free Hospital Hampstead, London, and most recently was a Clinical Fellow in Radiation Oncology at the British Columbia Cancer Agency, Vancouver. Richard is chair of numerous BioTech and Development Groups spanning several medical fields including cancer, oncology and radiotherapy.


Read more
Prof. Peter Hollands

Prof. Peter Hollands

Peter trained at Cambridge University under the supervision of Professor Sir Robert Edwards FRS, the inventor of IVF and Nobel Laureate, gaining a PhD from Cambridge University in stem cell technology. Peter held a post-doctorate position as a Senior Embryologist at the first IVF clinic in the world, Bourn Hall Clinic, and has carried out research in stem cell technology, has written numerous papers and book chapters on stem cell technology, and has been invited to lecture on stem cell technology in the Vatican, House of Lords and the Canadian Parliament. He has also been involved in clinical transplantation as Quality Manager in the Bone Marrow Transplantation Unit at Great Ormond Street Hospital for Children. Most recently, Peter was Chief Scientific Officer of Smart Cells Information Ltd., a UK cord blood bank, and Cells for Life Ltd. in Canada.


Read more